EWA
VTGN icon

Exencial Wealth Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Exencial Wealth Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,291
Closed -$271K – 482
2021
Q3 		$271K Sell
3,291
-941
-22% -$81.8K 0.01% 289
2021
Q2 		$400K Buy
4,232
+89
+2% +$6.59K 0.02% 346
2021
Q1 		$264K Buy
+4,143
New +$277K 0.02% 367

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

Exencial Wealth Advisors's VTGN Position: Q4 2021 in Review

Exencial Wealth Advisors sold out of VistaGen Therapeutics (VTGN) in Q4 2021, closing a stake of 3,291 shares — an estimated $271K sold.

Exencial Wealth Advisors first reported a position in VTGN in Q1 2021 and held it in 3 quarters. The position peaked at $400K in Q2 2021. 106 funds tracked by Wall St. Rank hold VTGN as of Q4 2021.

  • Exencial Wealth Advisors reported no remaining VistaGen Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Exencial Wealth Advisors sold 3,291 VistaGen Therapeutics shares in Q4 2021, an estimated $271K.
  • Exencial Wealth Advisors first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 3 quarters.
  • Exencial Wealth Advisors's VistaGen Therapeutics position peaked at $400K in Q2 2021.
  • 106 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2021.

Based on Exencial Wealth Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.